Opko Health Inc. (AMEX:OPK) jumped 21.83% up $2.12 on news the company has developed a simple blood test for Alzheimer’s disease, which assess the levels of antibodies unique to the disease with 95% accuracy. Headquartered in Miami, Florida, Opko Health, Inc., is a specialty healthcare company discovering, developing, and commercializing its proprietary pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis, and management of various disorders.

Rexahn Pharmaceuticals, Inc. (AMEX:RNN) rose 16.29% up to $0.919 on no news.  The stock’s intra-day high is sitting at $0.95 and trading above its 200 day moving average of $0.810. Based in Rockville, Maryland, Rexahn Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company which discovers, develops, and commercializes treatments for cancer, central nervous system disorders, sexual dysfunction in the US. The company currently has three drug candidates in Phase II clinical trials which include Serdaxin for the treatment of depression, Archexin for the treatment of renal cell carcinoma and pancreatic cancer; and Zoraxel for the treatment of sexual dysfunction.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Home Diagnostics, Inc. (NASDAQ:HDIX) rocketed 89.26% up to $11.45 on news the diabetes testing supplier has signed a merger agreement with Nipro Corporation, a global manufacturer and distributor of medical devices, pharmaceutical products and medical and glass products in Japan. Nipro will acquire all outstanding shares of Home Diagnostics’ common stock for $11.50 per share worth approximately $215 million. The offer price represents an approximately 90% premium to the closing price of Home Diagnostics’ common stock on February 2, 2010, and an approximately 83% premium to Home Diagnostics’ average closing price for the preceding 90 days. Based in Fort Lauderdale, Florida, Home Diagnostics, Inc. develops, manufactures, and markets blood glucose monitoring systems and disposable supplies for people with diabetes worldwide. Home Diagnostics supplies to the rapidly growing $7 billion diabetes testing supplies market.

The diabetes testing market in Japan is the largest in Asia. The market potential of the Japanese diabetes diagnostics market in 2005 was estimated at $401.9 million and is forecast to grow at an annual compound rate of 7% through 2012. The ever-increasing occurrence of diabetes in Japan, and throughout Asia and the resulting higher volumes of diagnostic tests are driving strong growth.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Somaxon Pharmaceuticals Inc. (NASDAQ:SOMX) blasted 102.27% up to $2.67 on news the sleep drug maker has refilled with the FDA seeking  approval for its New Drug Application (NDA)  on behalf of  Silenor (doxepin) for the treatment of insomnia.

On December 7^th 2009, the FDA declined Silenor for the second time that year; the stock spiralled down some 72% by mid-December, where it was trading around $0.928.  Fortunately the clinical safety of the drug was not an issue for the FDA; however the government agency was not satisfied with the efficacy standard for sustained sleep required to maintain effectiveness in adults with insomnia. 

Undaunted,  Somaxon  filed  ‘Class 1 resubmission’ this week and is prepared to begin commercialization of the drug candidate pending the decision, which is expected in about 8 weeks.

Somaxon currently has a market cap of about $62 million which is more than sufficient to finance its operations throughout the FDA’s current review of the Silenor and throughout the second quarter of 2010; and as of September 30^th 2009 the company had no debt. Headquartered in San Diego, California, Somaxon is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the central nervous system such as insomnia.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

MDRNA, Inc. (NASDAQ:MRNA) jumped 54.89% up to $1.47 with 18,036,294 shares trading this morning on news the company ‘s proprietary UsiRNA technology drastically reduced tumour growth in living models with liver and bladder cancer. This is the second study which has been established with a major international pharmaceutical company, and both in vivo trials revealed the efficacy and potency of the anti cancer treatment to shrink carcinogenic lesions.  The company says it’s on track to meet mid 2010 goals to the complete rigorous R&D schedule for their therapeutic candidate. Headquartered in Bothell, Washington, MDRNA, Inc is a biotechnology company which develops and commercializes therapeutic products based on RNA interference.  RNA molecules are linked together like DNA chains which are found in all living organisms and viruses.  RNA’s contribute to protein synthesis and the transmission of genetic information.  MDRNA stock has appreciated 450% since last March.

Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) surged 77.30% up to $3.28 on news  the results of a study by Johns Hopkins University researchers was published and demonstrated miRview  squamous accurately identified  non small cell lung cancer, with a much higher rate of precision than biopsies.  The impact of this discovery will help physicians make crucial lung cancer classification and diagnosis.  Based in Rehovot, Israel, Rosetta Genomics Ltd. develops microRNA-based diagnostic and therapeutic products in Israel. Rosetta Genomics develops diagnostic programs for various cancers, as well as for the identification of the origin of the primary tumour of metastases; for differentiating squamous from non squamous non-small cell lung cancer; and for differentiating mesothelioma from other tumours in the lungs and chest.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  Please visit us at PicksThatMove.com to view more of our profiled stocks.

Wellstar Leads OTC Winners With Volume

The hot stock information of the day includes:  WLSI, TSRD, TPHM

Wellstar International Inc. (OTC:WLSI) surged 100.00% up to $0.0002 on no news.  Based in Holland, Ohio, Wellstar International Inc, through its subsidiary, Trillennium Medical Imaging, develops and licenses advanced thermal imaging technology for consumer healthcare and veterinary markets in the US. The company installs infrared cameras and software for hospitals and clinics. The company’s diagnostic technology enables early breast cancer screening and detection; diagnosis of neuromuscular skeletal diseases, neurological disorders; and orthopaedic illnesses.

Tesoro Distributors Inc. (OTC:TSRD) jumped 66.67% to close at $0.0025 with 6,587,786 shares trading on no news. Based in Westport, Connecticut, Tesoro Distributors Inc is as a wholesale distributor of building materials, specifically hardwood, porcelain and natural stone flooring products and wall coverings to residential and commercial construction, remodelling and interior design markets.

Thomas Pharmaceuticals, Ltd. (OTC:TPHM) gained 50.00% up to $0.0006 with 2,089,792 shares moving this afternoon on no news. Based in Matawan, New Jersey, Thomas Pharmaceuticals, Ltd develops and markets over-the-counter non-prescription healthcare products in US.  The company has gained 500% since August.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  Please visit us at PicksThatMove.com to view more of our profiled stocks.

Super Hot Small Cap Technology Movers

The hot stock information of the day includes:  QXM, HBIO

Qiao Xing Mobile Communication Co Ltd. (NYSE:QXM) surged 35.10% up to $4.12 on no news; however the company announced favourable financial results for the second quarter of 2009 last week, with an increase in revenues up to $84.8 million.   The company also cut administrative spending down to $1.7 million.   Headquartered in Beijing, China, Qiao Xing Mobile Communication manufactures and sells mobile handsets.  It operates its business primarily through CEC Telecom Co., Ltd., or CECT, its 96.6% owned subsidiary in China.  In 2008 Qiao Xing Mobile introduced the VEVA brand series mobile phones and began to open its own retail stores to target the middle class income consumers in major cities in China. 

Harvard Bioscience Inc. (NASDAQ:HBIO) advanced 14.64% up to $4.15 on no news; however the company is expected to report Q3 results after the close of the market on Wednesday, November 4th. Headquartered in Holliston, Massachusetts, Harvard Bioscience develops, distributes, manufactures and markets specialized products and scientific instruments for application in life science research by pharmaceutical and biotechnology companies, universities and government laboratories worldwide.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  Please visit us at PicksThatMove.com to view more of our profiled stocks.

Positive Diagnostic For Healthcare Biotechnology: PODD, DCGN

The hot stock information of the day includes:   PODD, DCGN

Insulet Corporation (NASDAQ:PODD) jumped 18.71% to close at $10.66 on news the company reported an increase in revenue for their and profits for their Q3 financial results.  Highlights include an increase of 85% in revenue to $18.7 million, compared to $10.1 million in the third quarter of 2008. Gross profit for the third quarter of 2009 was $5.8 million, representing a 31% gross margin, compared to a gross loss of $0.1 million for the third quarter of the previous year.  For the nine months ended September 30, 2009, revenue increased 89% to $45.8 million from $24.2 million for the first nine months of 2008. Gross profit for the first nine months of 2009 was $11.0 million, a 24% gross margin compared to a gross loss of $5.8 million in the first nine months of 2008.  Headquartered in Bedford, Massachusetts Insulet Corporation is a medical device company which develops, manufactures, and markets an insulin infusion system for people with insulin-dependent diabetes in the US.

deCODE genetics, Inc. (NASDAQ:DCGN) gained 28.98% to close at $0.365 on no news. Based in Reykjavik, Iceland, deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock.

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  Please visit us at PicksThatMove.com to view more of our profiled stocks.

 Pharmaceuticals And BioTech Midday Gainers

The hot stock information of the day includes:  NYER, MBRX

Nyer Medical Group, Inc. (NASDAQ:NYER) jumped 181.71% up to $1.95 at midday on news today the company’s wholly owned subsidiary DAW, Inc., which conducts business under the name Eaton Apothecary, has entered into a deal with Walgreen Eastern Co., Inc. to purchase DAW’s operating assets.  Some of the assets are prescription files and the entire inventory of 12 Boston area pharmacies; $5.75 million of qualifying inventory and $1.1 million of operating equipment.  Nyer announced an agreement with investors for the sale of DAW’s stock following the closing of the Walgreens deal, and in effect Nyer will gain $1,500,000.  Based in Holliston, Massachusetts Nyer Medical Group, Inc., through its subsidiary, DAW, owns and controls a chain of retail pharmacies in Massachusetts.

Metabasis Therapeutics, Inc. (NASDAQ:MBRX) advanced 17.50% up to $0.869 at midday on no news; however the company is bullish and has gained 120% since September.  Headquartered in La Jolla, California, Metabasis Therapeutics, Inc., is a biopharmaceutical company which discovers, develops and commercializes drug therapeutics targeting the liver and liver pathways.  The company has collaborative research and development agreements with Roche Pharmaceuticals; Merck & Co.; Idenix Pharmaceuticals, Inc.; Daiichi Sankyo Company, Ltd.; Valeant Pharmaceuticals International; and Schering Corporation.  Metabasis Therapeutics currently has four drug candidates in clinical trials for the treatment of diabetes, and liver cancer and liver metabolic diseases.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  Please visit us at PicksThatMove.com to view more of our profiled stocks.

American Lithium And Encorium Make Gains On Heavy Volume: AMLM, ENCO

The hot stock information of the day includes: AMLM, ENCO

American Lithium Minerals Inc (OTC:AMLM) advanced 48.00% to close at $2.96 on no news.  Based in Henderson, Nevada, American Lithium Minerals Inc., is an early stage lithium exploration company which acquires, evaluates, and develops resource properties for the recovery of lithium in the US, Canada and South America.  A driver for the sector is the emergent electric car, and hybrid vehicle market around the world.

Encorium Group Inc. (NASDAQ:ENCO) bounced 15.29% to close at $0.490 on heavy volume.  It was disclosed that 3,937,500 shares were bought by Encorium insiders today.  Headquartered in Wayne, Pennsylvania, Encorium designs and manages clinical trials for lead pharmaceutical, biotechnology, and medical device industries primarily in the US and Europe.   Encorium Group stock has appreciated 269% July.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock.

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  Please visit us at PicksThatMove.com to view more of our profiled stocks.

DUSA And HH Lead Biopharmaceuticals And Healthcare Movers

The hot stock information of the day includes:  DUSA, RNN, HH

DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA) jumped 27.07% up to $1.69 on no news this morning.  Based in Wilmington, Massachusetts, DUSA Pharmaceuticals, Inc., is a dermatology pharmaceutical company, which develops and markets dermatological treatments for the treatment of pre-cancerous skin lesions known as Actinic Keratoses, moderate inflammatory acne vulgaris and general dermatological conditions.  The company’s proprietary product line includes Levulan and  KerastickBLU-U light therapies and ClindaReach, a medicated swab device which allows for the application of topical clindamycin phosphate solution to hard to reach places on the skin’s surface. 

Rexahn Pharmaceuticals, Inc. (AMEX:RNN) rose 20.57% up to $0.940 on news the company’s  drug candidate Serdaxin showed positive results in a Phase IIa clinical study which has assessed the product’s safety and efficacy for the treatment of severe depression. Based in Rockville, Maryland, Rexahn Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company which discovers, develops, and commercializes treatments for cancer, central nervous system disorders, sexual dysfunction in the US. The company currently has three drug candidates in Phase II clinical trials which include Serdaxin for the treatment of depression, Archexin for the treatment of renal cell carcinoma and pancreatic cancer; and Zoraxel for the treatment of sexual dysfunction.

Hooper Holmes, Inc. (AMEX:HH) advanced 28.56% up to $0.900 on no official news.  Headquartered in Basking Ridge, New Jersey, Hooper Holmes, Inc., together with its subsidiaries, provides outsourced risk assessment services to the life and health insurance industry in the US and provides paramedical and medical examinations of applicants for insurance, primarily life insurance, through a network of paramedical examiners, including phlebotomists, registered nurses, licensed practitioner nurses, emergency medical technicians, and other medically trained professionals.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock.